CN106456642A - 含btk抑制剂与akt抑制剂的组合 - Google Patents

含btk抑制剂与akt抑制剂的组合 Download PDF

Info

Publication number
CN106456642A
CN106456642A CN201580013442.2A CN201580013442A CN106456642A CN 106456642 A CN106456642 A CN 106456642A CN 201580013442 A CN201580013442 A CN 201580013442A CN 106456642 A CN106456642 A CN 106456642A
Authority
CN
China
Prior art keywords
compound
cancer
base
chloro
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580013442.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·库马
K·A·罗贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN106456642A publication Critical patent/CN106456642A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580013442.2A 2014-03-12 2015-02-24 含btk抑制剂与akt抑制剂的组合 Pending CN106456642A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951640P 2014-03-12 2014-03-12
US61/951,640 2014-03-12
PCT/IB2015/051380 WO2015136398A1 (en) 2014-03-12 2015-02-24 Combination comprising a btk inhibitor and an akt inhibitor

Publications (1)

Publication Number Publication Date
CN106456642A true CN106456642A (zh) 2017-02-22

Family

ID=52630445

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580013442.2A Pending CN106456642A (zh) 2014-03-12 2015-02-24 含btk抑制剂与akt抑制剂的组合

Country Status (10)

Country Link
US (2) US20170020878A1 (cg-RX-API-DMAC7.html)
EP (1) EP3116546A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017507963A (cg-RX-API-DMAC7.html)
KR (1) KR20160127754A (cg-RX-API-DMAC7.html)
CN (1) CN106456642A (cg-RX-API-DMAC7.html)
AU (1) AU2015228475B9 (cg-RX-API-DMAC7.html)
CA (1) CA2942204A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016011674A (cg-RX-API-DMAC7.html)
RU (1) RU2016139697A (cg-RX-API-DMAC7.html)
WO (1) WO2015136398A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646427A (zh) * 2007-02-07 2010-02-10 史密丝克莱恩比彻姆公司 Akt活性抑制剂
CN102405047A (zh) * 2009-01-30 2012-04-04 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
WO2013010869A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ, インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
CA2852964A1 (en) 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Bicyclic piperazine compounds
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2013161848A1 (ja) 2012-04-27 2013-10-31 カルナバイオサイエンス株式会社 新規1,2,4-トリアジン誘導体
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646427A (zh) * 2007-02-07 2010-02-10 史密丝克莱恩比彻姆公司 Akt活性抑制剂
CN102405047A (zh) * 2009-01-30 2012-04-04 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKINTUNDE AKINLEYE等: "Ibrutinib and novel BTK inhibitors in clinical development", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》 *
JAIKRIT BHUTANI等: "Akt inhibitors: mechanism of action and implications for anticancer therapeutics", 《BHUTANI ET AL. INFECTIOUS AGENTS AND CANCER》 *
LESLEY A. MATHEWS GRINERA等: "High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells", 《PNAS》 *

Also Published As

Publication number Publication date
US20170020878A1 (en) 2017-01-26
KR20160127754A (ko) 2016-11-04
WO2015136398A1 (en) 2015-09-17
JP2017507963A (ja) 2017-03-23
AU2015228475B2 (en) 2017-08-17
AU2015228475A1 (en) 2016-09-01
US20190151319A1 (en) 2019-05-23
RU2016139697A (ru) 2018-04-12
RU2016139697A3 (cg-RX-API-DMAC7.html) 2018-10-19
AU2015228475B9 (en) 2017-09-21
CA2942204A1 (en) 2015-09-17
EP3116546A1 (en) 2017-01-18
MX2016011674A (es) 2017-04-27

Similar Documents

Publication Publication Date Title
CN106061481B (zh) 用于治疗癌症的雄激素受体抑制剂与akt抑制剂的组合
CN102405047B (zh) 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
JP7235807B2 (ja) 組合せ物
HK40012995A (en) Combinations for treating cancer and use thereof
HK40007974A (en) Combination
AU2015228475B2 (en) Combination comprising a BTK inhibitor and an AKT inhibitor
HK40038736A (en) Combination
CN104902896A (zh) 组合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222

WD01 Invention patent application deemed withdrawn after publication